THIADIAZOLE OXIDES AS GASTRIC ANTISECRETORY AGENTS

Abstract: There are disclosed novel thiadiazole oxide compounds having the formula: wherein: B¹ is R A ○ (CH₂) n X (CH₂) m -; and, B² is R wherein: R is hydrogen, loweralkyl: wherein R₁ and R₂ are independently e.g. hydrogen, loweral­ kyl, cycloloweralkyl, or phenylloweralkyl, or R₁ and R₂ may be joined to form, along with the nitrogen to which they are attached, a 5- or 6-membered heterocycle; R₃ and R₄ are independently hydrogen or loweralkyl; n is 0 or 1; m is 2 to 4; k is 1 to 4; X is oxygen, sulfur or methylene; p is 1 or 2; A ○ is phenylene or a 5- or 6-membered heterocycle containing one to three heteroatoms selected from oxygen, sulfur or nitrogen, which may optionally have a benzo ring fused thereon; provided that when A ○ is a 5-membered heterocycle or benzo fused 5-membered heterocycle, n is 1 and processes for the preparation of such compounds. The compounds are useful for the suppression of gastric acid secretions in mammals.

Description: TITLE OF THE INVENTION THIADIAZOLE OXIDES AS GASTRIC ANTISECRETORY AGENTS. BACKGROUND OF THE INVENTION Compounds containing a heterocycle connected to a cyanoguanidine moiety through a linear or cyclic connecting group are known in the art as H2 histamine receptor inhibitors and are active compounds for the suppression of gastric acid secretions. See for example U.S. Patent 3,950,333 to Durant et. al., U.S. Patent 4,128,658 to Price et. al., and European Patent 3640 to Jones et. al. In addition, Belgian Patent 875,846, as abstracted in Derwent Abstract 79110B/44, discloses compounds wherein a triazole heterocyclic ring is incorporated into compounds similar to those disclosed in Durant et. al., and Jones et. al., in place of the guanidino end group. Further, U.S. Patent 4,025,527 to Durant et. al. and European Patent 2930 (Derwent Abstract 53014B/29) disclose substituted guanidines and substituted l,l-diaminoethylenes in which two nitrogen atoms are each joined to a carbocycle or heterocycle through a linear connecting group. In addition, Belgian Patent 885,089 discloses diamino thiadiazole oxide compounds wherein both the amino groups are connected to substituted carbo or hetero cyclic groups through linear connecting chains. However, these prior art compounds are distinctly different from and do not suggest those of the present invention in which one of the connecting chains is phenylene. The thiadiazole oxide compounds of this invention have been found to possess considerable activity in the suppression of gastric acid secretions. Thus, they are useful in peptic ulcer therapy and in other gastric hypersecretory states such as Zollinger Ellison syndrome, and in protection against drug induced gastric lesions. SUMMARY OF THE INVENTION This invention is directed to diamino thiadiazole oxide compounds wherein both amino groups are connected to a substituted or unsubstituted phenyl or heterocyclic moiety through a linear and a cyclic connecting group and to processes for the preparation of such compounds. DESCRIPTION OF THE INVENTION The compounds of this invention are represented by the following structural formulae: EMI2.1 wherein: B1is RO A (CH2)n X (CH2)m¯; EMI3.1 R is hydrogen, loweralkyl, EMI3.2 wherein: R1 and R2 are independently hydrogen, loweralkyl, cycloloweralkyl or phenylloweralkyl or R1 and R2 may be joined to form, along with the nitrogen to which they are attached, a 5- or 6-membered heterocycle, which may also contain an oxygen, sulfur or an N-R5 heteroatom, selected from pyrrolidino, piperidino, thiomorpholino, morpholino, or N-loweralkyl-piperazino wherein R5 is hydrogen or loweralkyl of from 1 to 3 carbon atoms; R3 and R4 are independently hydrogen or loweralkyl; n is O or 1; m is 2 to 4; k is 1 to 4; X is oxygen, sulfur or methylene; p is 1 or 2; ; is is phenylene or a 5- or 6-membered hetero- cycle containing one to three heteroatoms selected from oxygen, sulfur or nitrogen, which may optionally have a benzo ring fused thereon; provided that when A in Formula I above is a 5-membered heterocycle or a benzo fused 5-membered heterocycle, n is 1; and, provided further that when in Formula I is a furan having the structure EMI4.1 then R6 is the same as R defined above and R7 is loweralkyl, alkoxyalkyl, alkoxycarbonyl, halo, preferably chlorine or bromine, or aryl, preferably phenyl. in in the foregoing formulae when heterocyclic may be furan, thiophene, pyrrole, oxazoler oxadiazole, thiadiazole, thiazole, triazole, pyrazole, imidazole, pyridine, pyrimidine, pyrazine, and the like, and the fused benzo derivatives thereof such as benzofuran, benzoxazole, benzimidazole, and the like. In the instant invention, unless specified otherwise, the term "loweralkyl" is intended to include those alkyl groups containing from 1 to 5 carbon atoms in either a straight or branched configuration. Examples of such alkyl groups are methyl, ethyl, propyl, iso-propyl, butyl, sec-butyl, pentyl and the like. The term "cycloloweralkyl" is intended to include those cycloalkyl groups of from 3 to 7 carbon atoms. Examples of such cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. In Formula I preferred compounds are realized when p is 1 or 2. Further, such preferred compounds are those wherein A in B1 is m-phenylene or a 6-membered heterocycle as defined above, n is O, X is oxygen, m is 3 and R is: EMI5.1 In such cases it is further preferred that k be 1 and R1 and R2 be loweralkyl, preferably methyl, or joined to form a morpholine, thiomorpholine, piperidine or N-methyl piperazine ring. Additional preferred variations are those wherein A is furan, imidazole, thiazole, oxazole, thiophene, triazole, thiadiazole, oxadiazole or benzofuran. When A is heterocyclic it is preferred that n=l, X=sulfur and m=2. The preferred values of R will depend upon and vary with the definition of When A is furan or benzofuran, R is preferred to be: EMI5.2 and is attached at the 5- and 6-positions, respectively. It is further preferred that k=l and R1 and R2 be hydrogen or loweralkyl, preferably hydrogen or methyl, or joined to form a morpholine, thiomorpholine, piperidine or N-methyl piperazine ring. When A is imidazole, R is preferably loweralkyl, most preferably methyl. When A is thiazole, R is preferably: EMI6.1 where R3 and R4 are most preferably hydrogen. In Formula I it is preferred that p is 1 or 2. It is further preferred that the phenyl ring in B be- connected to the adjacent groups at its meta position. The preferred values of R in Bê will vary with the nature of 0A The preferred values of A are imidazole, and thiazole. When is imidazole, it is preferred that R be loweralkyl, most preferably methyl. When A is thiazole, it is preferred that R be: EMI6.2 and wherein it is most preferred that R3 and R4 be hydrogen. Preferably, R, , X, m and n in B1 are as defined for B1 in Formula I. Following is an exemplary list of preferred compounds of this invention: 3-N-[2-[(4-methyl-5-imidazolyl)methylthio]ethyl3amino- 4-N-[3-(2-guanidino-4-thiazolyl)phenyl]aminO-l r 2 r5¯ thiadiazole-l-oxide; 3-N-[2-[ (5-dimethylaminomethyl-2-furanyl)methylthio]- ethyl]amino-4-N-!3-(2-guanidino-4-thiazolyl)phenyl]amino- 1,2, 5-thiadiazole-l-oxide; 3-N-[2-[(2-guanidino-4-thiazolyl)methylthiOaethYll- amino-4-N-[3-(2-guanidino-4-thiazolyl)phenyl]amino-1,2,5- thiadiazole-l-oxide; 3-N-[3-(2-guanidino-4-thiazolyl)phenyllamino-4-N-f3- [3-(dimethylaminomethyl)phenoxy]propyl]amino-l,2,5- thiadiazole-l-oxide; 3-N-[2-[(4-methyl-5-imidazolyl)methylthiolethyllamino- 4-N-13-[(2-guanidino-4-thiazolyl)phenyllamino-1,2,5- thiadiazole-l,l-dioxide; 3-N- [2-! (5-di: :nethylaminomethyl-2-furanyl)methylthioi - ethyl]amino-4-N-13-(2-guanidino-4-thiazolyl)phenylaamino- 1,2, 5-thiadiazole-l, 1-dioxide; 3-N-[2-[ (2-guanidino-4-thiazolyl)methylthioiethyli- amino-4-N-[3-(2-guanidino-4-thiazolyl)phenyl]amino-1,2,5- thiadiazole-l,l-dioxide; 3-N-[3-[ (2-guanidino-4-thiazolyl)phenyl]amino-4-N-[3- [3-(dimethylaminomethyl)phenoxy]propyl]amino-1,2,5- thiadiazole-l,l-dioxide. The compounds of the invention containinq hasic groups readily form physiologically acceptable salts. Such salts include salts with inorganic acids such as hydrochlorides, hydrobromides, sulfates, nitrates and phosphates. Particularly useful salts of organic acids are formed with aliphatic mono- or dicarboxylic acids. Examples of such salts are acetates, maleates, fumarates, tartrates, citrates, benzoates, succinates and isethionates. The compounds and their salts can also form hydrates and solvates. In addition, the nitrogen atoms in groups R andmay also form quaternary salts and N-oxides. It will also be appreciated by those skilled in the art that the compounds of this invention will have a tautomeric isomerism about the nitrogen atoms adjacent to the thiadiazole ring. Where one or both of the adjacent nitrogen atoms has a hydrogen atom thereon, the exo-imino structure can be formed on one or both of such nitrogen atoms as shown in the following structure: EMI8.1 All of the various tautomeric structures of the instant compounds are intended to be included in this invention. When R is guanidino, three tautomeric structure variations are possible, and all such tautomers are included in this invention. In addition, when p is 1, there exists the possibility of stereoisomerism in the instant compounds, corresponding to an R or S absolute configuration at the sulfur atom of the thiadiazole ring. All such stereoisomers are also indluded within the instant invention. As stated above, the compounds represented by Formulae I and II have been found to have pharmacological activity in the animal body as antagonists to certain actions of histamine which are not blocked by "antihistamines" such as mepyramine. For example, they have been found to inhibit selectively the histaminestimulated secretion of gastric acid in the stomach of chronic fistula dogs at doses of from 0.03 to 1.0 mg per kilogram intravenously. Similarly, the action of these compounds is demonstrated by their antagonism to the effects of histamine on other tissues which are not affected by histamine H1 antagonists. An example of such tissue is the isolated guinea-pig right atriun. These compounds have been found to be up to 5C times more active in animal models than currently marketed gastric antisecretory H2 antihistamines. The pharmaceutical carrier employed can be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form, or in the form of.a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 15 mg to about 0.4 gm. If a liquid carrier is used, the preparation can be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectahle liquid such as an ampoule, or an aqueous or nonaqueous liquid suspension. The pharmaceuticai compositions are prepared by conventional techniques involvinq procedures such as mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. The active ingredient will be present in the composition in an effective amount to inhibit histamine gastric acid secretory activity. The route of administration can be orally or parenterally. Preferably, each daily dosage will contain the active ingredient in an amount of from about 2 mg to about 1000 mg, most preferably from about 40 to about 500 mg given in a single dose or multiple divided doses. For therapeutic use, the pharmacologically active compounds of the present invention will normally be administered as a pharmaceutical composition comprising, as the sole or as an essential active ingredient, at least one such compound in the basic form or in the form of an addition salt with a pharmaceutically acceptable acid and in association with a pharmaceutical carrier therefor. Such addition salts include those mentioned above. The compounds of this invention can also be employed with other pharmacologically active compounds. Exemplary of such other pharmacological compounds are anticholinergic agents such as propantheline; H1 antihistamines such as mepyramine, pyribenzamine, chlorpheniramine, and the like; prostanoids such as prostaglandin El, prostaglandin A, and the like; histidine decarboxylase inhibitors such as a-fluoromethyl histidine, Brocresin (3-hydroxy-4-bromobenzyloxyamine), a-hydrazino histidine, and the like; antiulcer agents such as carbenoxolone, Vitamin U, and the like; antacids such as calcium carbonate preparations, aluminum hydroxide, and the like; nitrosation inhibitors such as Vitamin C; antigastrins such as somatostatin; as well as combinations and mixtures thereof. Advantageously, a pharmaceutical composition will be made up in a dosage unit form appropriate to the desired mode of administration, such as, for example, a tablet, capsule, or injectable solution. The compounds of the invention are prepared by seqùentially reacting a thiadiazole substituted with leaving groups L1 amd L2 with appropriately substituted amines. The reaction applies to those compounds wherein p is 1 or 2 and is outlined in the following reaction scheme: REACTION SCHEME I: EMI12.1 In the foregoing Reaction Scheme, B1 and B2 are as defined above, p is 1 or 2, and L1, and L2 are leaving groups. Appropriate leaving groups for this reaction are exemplified by loweralkoxy, loweralkylthio, phenoxy, phenylthio and halogen. Such loweralkoxy and loweralkylthio leaving groups are those containing from 1 to 5 carbon atoms in either a straight or branched configuration. Examples of such groups are methoxy, ethoxy, propoxy, iso-propoxy, butoxy, sec-butoxy, pentoxy, methylthio, ethylthio, propylthio, isopropylthio, phenoxy, phenylthio, and the like. The term "halogen" includes the halogen atoms chlorine, fluorine, and bromine. Preferred leaving groups are methoxy, ethoxy, methylthio, fluorine, chlorine and bromine. As shown in the foregoing Reaction Scheme, the diaminothiadiazole compounds are prepared by first displacing one of the leaving groups of Compound II with 2 an amine B2NH2 to afford III followed by displacement of the remaining leaving group by a different amine B1NH2 to produce the desired compounds. This NH2 reaction is carried out on the thiadiazole sulfoxide or sulfone. With reference to the Reaction Scheme, the reagents are combined, preferably in an aprotic solvent such as tetrahydrofuran, acetonitrile, ethylacetate, ether, and the like, at from -780 to +1000C, preferably from -780 to 1000C. Preferably, 1 equivalent of the amine is added over a period of from 5 minutes to 2 hours. The progress of the reaction can be followed by taking aliquots of the reaction mixture and analyzing them on thin layer chromatography plates. When the reaction is complete, the reaction mixture is allowed to warm and the product is recovered using techniques known to those skilled in the art. The reaction with the second amine is generally slower than with the first. The reactivity in each case is determined, however, by the particular thiadiazole substrate and the nature of the amine being reacted therewith. The reaction with the second amine is carried out in a protic or non-protic solvent such as methanol, ethanol, ether, ethylacetate, tetrahydrofuran, and the like. The reaction is generally carried out at from OOC to 1000C and is complete in from 5 minutes to 2 or more days. If the desired reaction temperature is higher than the boiling point of the reaction mixture, the reaction can be carried out in a pressure vessel. Reactions with the thiadiazole sulfones are generally faster than those with the corresponding sulfoxide and, as a result, the reaction with sulfones are generally complete in shorter times and at lower temperatures than with the sulfoxides. The products are isolated using techniques known to those skilled in the art. An alternate procedure for the reaction of the first amine with the starting material (II) in which p=2 consists of reacting the trialkylsilyl derivative of the 2 amine B NH2 with Compound II in an aprotic solvent at 250-1000C for about 1 to 24 hours. Required amine trimethylsilyl derivatives are prepared by reacting the amine hydrohalide, preferably hydrochloride, with an excess of the reagent such as hexamethyldisilazane. The reaction is carried out without any solvent from about room temperature to 1500C for from about 1/2 to 24 hours. The thus produced trialkylsilylamine is then reacted with Compound II as described above and the desired product is isolated using techniques known to those skilled in the art. The thiadiazole starting materials wherein p=2 with two leaving groups thereon are compounds generally known in the art. For example see Carmack et al. J. Org. Chem. 30 2743 (1975). The complex amines which are reacted with the thiadiazole starting material are also compounds known in the art. See for example the Durant et. al., Price et. al. and Jones et. al. references discussed in the Background of the Invention. Of course, other amine starting materials, similar to those discussed in the foregoing references, can be prepared using the procedures described in such references. The thiadiazole starting materials wherein p is 1 with two leaving groups thereon are novel compounds. Such compounds are prepared by reacting an appropriately disubstituted oxalimidate or oxalthio-imidate with thionyl chloride to prepare the thiadiazole compounds with two leaving groups as shown below: EMI15.1 wherein L1 and L2 are as defined above. The appropriately disubstituted oxalimidate or oxalthioimidate is reacted with thionyl chloride in the presence of a base to neutralize the hydrogen chloride liberated during the course of the reaction. The base may be any organic or inorganic base which does not react with any of the starting materials or products. Generally, tertiary amines such as triethylamine and pyridine or inorganic bases such as alkali metal carbonates or bicarbonates are employed. The reactants are generally dissolved in a suitable solvent such as methylene chloride, chloroform, toluene, ether, tetrahydrofuran, acetonitrile and the like, or any other solvent which is non-reactive to the starting materials and products. The reaction is carried out at from -780C (dry-ice bath) to 1000C or at the reflux temperature of the reaction mixture. The reaction is preferably carried out at from OOC to room temperature and is generally complete in about from 1/2 to 10 hours. The thionyl chloride is generally used in slight excess although greater amounts of the reagent are not detrimental. The following examples are set forth to further illustrate the invention and are not to be construed as being limitative thereof. Unless otherwise indicated, all temperatures are in degrees Celsius. EXAMPLE 1 3-N-[2-[ (5-Dimethylaminomethyl-2-furanyl)methylthio] - ethyl3amino-4-N-t3-(2-guanidino-4-thiazolyl)phenyl3amino- 1,2,5-thiadiazole-l-oxide A. 4-N-[3-(2-Guanidino-4-thiazolyl)phenyl]amino-4- methoxy-1,2,5-thiadiazole-l-oxide A solution of 2.33 g. (0.010 mol.) of 3-(2-guanidino-4-thiazolyl)benzeneamine in 50 ml. of methanol is added to a suspension of 1.94 g. (0.010 mol) of 3,4-bis(methylthio) -l,2,5-thiadiazole-l-oxide in 20 ml. of methanol with stirring. All solids dissolve and the solution is stirred for 120 hours. No change in the reaction mixture is noted by thin layer chromatography during the last 24 hours. The reaction mixture is filtered to give 0.71 g. of orange solids which gives only an origin spot on thin layer chromatography. The filtrate is evaporated to dryness under vacuum to give 3.30 g. of yellow solid. Nuclear magnetic resonance of the material shows the presence of the product. The material is purified on a column of activity III neutral alumina. Elution with chloroform, followed by 1% methanol/chloroform and 5% methanol/chloroform gives thiadiazole starting material. Elution with 10%, 208 and 50% methanol/chloroform gives 2.32 g. (14%) of yellow solid containing product. Recrystallization from acetonitrile gives 1.20 g.; m.p. 217-2210(d) of 4-N-[3-(2-guanidino-4-thiazolylphenyl]amino-3-methoxy-1,2, 5-thiadiazole-l-oxide; proton nuclear magnetic resonance is consistent with this structure. It is noted that during the course of this reaction the solvent (methanol) exchanged with the methylthio group which was not reacted with the amine to prepare the 4-methoxy compound. This does not effect the reaction, since the second amine can react with either the 4-methoxy compound or the 4-methylthio compound. B. 3-N-[2-[(5-Dimethylaminomethyl-2-furanyl)methylthio]- ethyl]amino-4-N-[3-(2-guanidino-4-thiazolyl)phenyl] amino-1,2,5-thiadiazole-l-oxide The product from part A above is reacted with an equimolar amount of 2-[(5-dimethylaminomethyl-2furanyl)methylthio]ethylamine in acetonitrile and stirred at room temperature for 3 days. The mixture is then concentrated under vacuum and the residue is chromatographed on silica with 5% methanol - 95% chloroform. The product fractions are combined and concentrated under vacuum and the title product is isolated by chromatography on silica. EXAMPLE 2 3-N-[3- (2-Guanidino-4-thiazolyl)phenyl]amino-4-N-[3- [(3-dimethylaminomethyl)phenoxy]propyl]amino-1,2,5- thiadiazole-l,l-dioxide A. 3-N-[3- (2-guanidino-4-thiazolyl)phenyl]amino-4-ethoxy- -1, 2,5-thiadiazole-1,1-dioxide A solution of 1.17 g. (0.005 mol.) of 3-(2-guanidino-4-thiazolyl)benzeneamine in 30 ml. of ethanol is added to a slurry of 1.03 g. (0.005 mol.) of 3,4-diethoxy-l,2,5-thiadiazole-l,l-dioxide in 30 ml. of ethanol with stirring. All solids dissolve within one minute and a precipitate begins to form within two minutes. The reaction mixture is stirred for 5 hours, at which time the reaction is complete by thin layer chromatography. The precipitate is filtered, dried and recrystallized from ethanol to give 1.35 g. of 3-N-[3 (2-guanidino-4-thiazolyl)phenyl]amino-4-ethoxy-1,2,5thiadiazole-l,l-dioxide m.p. 237-2390C. B. 3-N-[3-(2-Guanidino-4-thiazolyl)phenyl]amino-4-N-[3- [(3-dimethylaminomethyl)phenoxy]propyllamino-1,2,5- thiadiazole-l,l-dioxide. The product from part A above is reacted with an equimolar amount of 3-1(3-dimethylaminomethyl)- phenoxy]propylamine in acetonitrile essentially under the conditions described in Example 1, part B. The title product is isolated by chromatography on silica. The following preparations are set forth to illustrate the methods which can be employed to obtain the intermediate compounds used in the invention and are not to be construed as being limitative. Unless otherwise indicated, all temperatures are in degrees Celsius. PREPARATION 1 3,4-Diethoxy (1,2,5) thiadiazole-l-oxide To a solution of 441 g. (3.06 moles) of diethyl oximidate in 300 ml. of methylene chloride and 780 ml. (9.63 mol.) of pyridine is added dropwise with cooling 195 ml. (3.2 mol.) of thionyl chloride at 100+50C. The reaction mixture is stirred for 2 hours at room temperature. The mixture is partitioned between dilute hydrochloric acid and methylene chloride. The methylene chloride is washed once with dilute hydrochloric and, twice with saturated sodium bicarbonate solution and once with saturated sodium chloride solution. The organic layer is dried with magnesium sulfate, concentrated to a low volume and diluted with hexane. The crystals are removed by filtration, washed in water and dried in vacuo to yield 410 g. of 3,4-diethoxy-1,2,5-thiadiazole-1-oxide m.p. = 74-780C. A sample is recrystallized from cyclohexane to yield white crystals m.p. = 75-78"C. Mass spectrum 190 (M+ C6HloN2OS), 161 (M+ -C2H5) -l IR (CHC13) 1625 (C=N), 1060 CM 1 (SO) Proton N.M.R. (CDC13) ,S4.5 (q, J=7Hz, 4H), 1.5 (t, J=7Hz, 6H) PREPARATION 2 3,4-Bis-methylthio-1,2,5-thiadiazole-1-oxide To a solution of 353 g. [2.39 moles] of dithiomethyl oximidate in 1500 ml. of methylene chloride and 580 ml. of pyridine [7.2 moles] is added dropwise 188 ml. [2.59 moles] of thionyl chloride at 0 + 50C. The temperature of the mixture is raised to room temperature and stirred for 2 hours. The mixture is partitioned between methylene chloride and dilute hydrochloric acid. The organic layer is washed once with dilute hydrochloric acid, twice with saturated sodium bicarbonate and once with saturated sodium chloride solution. The organic layer is dried with magnesium sulfate and concentrated to a low volume and diluted with ether. The crystals are filtered, washed with ether and dried to yield 401 g. of 3,4-bis methylthio-1,2,5-thiadiazole-1-oxide m.p.=109-1120C. Mass spectrum 194 (M+ C4H6OS3) IR (CHC13) 1625 (C=N), 1050 CM (SO) Proton N.M.R. (CDC13) 2.7 ppm S

Claims: WHAT IS CLAIMED IS: 1. A compound having the formula: EMI21.1 wherein: B1 is R & ommat; (CH2)n X (CH2)m; and, B2 is EMI21.2 wherein: R is hydrogen, loweralkyl: EMI21.3 wherein R1 and R2 are independently hydrogen, loweralkyl, cycloloweralkyl; or phenylloweralkyl, or R1 and R2 may be joined to form, along with the nitrogen to which they are attached, a 5- or 6-membered heterocycle, which may also contain an oxygen, sulfur or N-R7 heteroatom, wherein R7 is hydrogen, loweralkyl of from 1 to 3 carbon atoms or benzyl; R3 and R4 are independently hydrogen or loweralkyl; n is O or 1; m is 2 to 4; k is 1 to 4; X is oxygen, sulfur or methylene; p is 1 or 2; is phenylene or a 5- or 6-membered heterocycle containing one to three heteroatoms selected from oxygen, sulfur or nitrogen, which may optionally have a benzo ring fused thereon; provided that when A is a 5-membered heterocycle or benzo fused 5-membered heterocycle, n is 1; and, the physiologically acceptable salts thereof. 2. The compound of Claim 1 wherein is independently phenyl, furan, thiophene, pyrrole, oxazole, oxadiazole, thiazole, thiadiazole, triazole, pyrazole, imidazole, pyridine, pyrimidine, pyrazine or benzofuran. 3. The compound of Claim2 wherein in B2 is thiazole and R is EMI22.1 and,0Aifl BI BÚ is phenyl, furan, thiophene, pyrrole, oxazole, oxadiazole, thiazole, thiadiazole, triazole, pyrazole, imidazole, pyridine, pyrimidine, pyrazine, or benzofuran. 4. The compound of Claim 3whereinGin B1 is 2,5-furan, R is EMI23.1 n is 1, X is sulfur, m is 2; and, R3 and R4 are hydrogen. 5. The compound of Claim 3 wherein A in B1 is m-phenylene, R is EMI23.2 n is 0, X is oxygen, m is 3, k, R1 and R2 are as defined in Claim 1; and, R3 and R4 are hydrogen. b. A compound of Claim4 which is 3-N-[2 [(5-dimethylaminomethyl-2-furanyl)methylthio]ethyl]amino-4 -N-[3-(2-guanidino-4-thiazolyl)phenyl]amino-l,2,5- thiadiazole-l-oxide. T. A compound of Claim 5 which is 3-N-[3-(2guanidino-4-thiazolyl)phenyl]amino-4-N-[3-[3-(dimethyl aminomethyl)phenoxy]propyl]amino-1,2,5-thiadiazole-1- oxide. 8. A process for the preparation of a compound of Claim 1 which comprises treating a compound having the formula: EMI23.3 wherein p is 1 or 2 and L1 and L2 are leaving groups, consecutively with the amine compound Bê B1 . the amine compound 1 followed by the amine compound BÚ -NH2 wherein BÚ, and Bê are as defined in Claim 1. 9. A composition useful for suppressing gastric acid secretions in an animal with excess gastric acid secretions which comprises an inert carrier and an antisecretorily effective amount of a compound of Claim 1. 10. A composition useful for suppressing gastric acid secretions in an animal with excess gastric acid secretions which comprises an inert carrier; an antisecretorily effective amount of a compound of Claim 1; and, a pharmacologically active compound selected from the group consisting of propantheline, mepyramine, pyribenzamine, chlorpheneramine, prostaglandins, a-fluormethyl histidine, 3-hydroxy-4-bromobenzyloxyamine, a-hydrazino histidine, carbenoxolone, Vitamin U, calcium carbonate preparations, aluminum hydroxide, Vitamin C, somatostatin, as well as combinations and mixtures thereof. CLAIMS FOR AUSTRIA 1. A process for the preparation of a ccmpoin having the formula: EMI25.1 wherein: B is RAA (CH2)n X (cH2)m-; and, B2 is EMI25.2 wherein: R is hydrogen, loweralkyl: : EMI25.3 wherein R1 and R2 are independently hydrogen, loweralkyl, cycloloweralkyi; or phenylloweralkyl, or R1 and R2 may be joined to form, along with the nitrogen to which they are attached, a 5- or 6-membered heterocycle, which may also contain an oxygen, sulfur or N-R7 heteroatom, wherein R7 is hydrogen, loweralkyl of from 1 to 3 carbon atoms or benzyl; R3 and R4 are independently hydrogen or loweralkyl; n is O or 1; m is 2 to 4; k is 1 to 4; EMI26.1 X is oxygen, sulfur or methylene; p is 1 or 2; is phenylene or a 5- or 6-membered heterocycle containing one to three heteroatoms selected from oxygen, sulfur or nitrogen, which may optionally have a benzo ring fused thereon; provided that when A is a 5-membered heterocycle or benzo fused 5-membered heterocycle, n is 1; and, the physiologically acceptable salts thereof, which comprises treating a compound having the formula: EMI26.2 wherein L1 and L2 are leaving groups, consecutively with the amine compound B2-NH2 followed by the amine compound B1-NH2. 2. The process of Claim 1 wherein the heterocycle formed when R1 and R2 are joined is a pyrrolidine, piperidine, morpholine, thiomorpholine or piperazine. 3. The process of Claim 1 wherein R3 and R4 are independently hydrogen and loweralkyl. 4. The process of Claim 1 wherein A is indepently phenyl, -furan, thiophene, pyrrole, oxazole, oxadiazole, thiazole, thiadiazole, triazole, pyrazole, imidazole, pyridine, pyrimidine, pyrazine or benzofuran. 5. The process of Claim 4 wherein in Bê is thiazole and R is EMI27.1 and,in in BÚ is phenyl, furan, thiophene, pyrrole, oxazole, oxadiazole, thiazole, thiadiazole, triazole, pyrazole, imidazole, pyridine, pyrimidine, pyrazine, or benzofuran. 6. The process of Claim 5 wherein A in B1 is 2,5-furan, R is EMI27.2 n is 1, X is sulfur, m is 2; and, R3 and R4 are hydrogen. 7. The process of Claim 5 wherein A in B1 is m-phenylene, R is EMI27.3 n is 0, X is oxygen, m is 3, k, R1 and R2 are as defined in Claim 1; apd, R3 and R4 are hydrogen. 8. The process of Claim 1 for preparina 3-N-[2 [(5-dimethylaminomethyl-2-furanyl)methylthio]ethyl]amino-4 -I{-[3-(2-guanidino-4-thiazolyl)phenyl]amino-1,2,5- thiadiazole-l-oxide. 9. The process of Claim 1 for preparing 3-N-[3-(2guanidino-4-thiazolyl)phenyl]amino-4-N-[3-[3-(dimethyl aminomethyl)phenoxy]propyl]amino-1,2,5-thiadiazole-1- oxide. EMI27.4

Inventors: BALDWIN, JOHN J., BOLHOFER, WILLIAM A., LUMMA, WILLIAM C., JR.
Applicants: MERCK & CO. INC.
Application year: 1982
Main classification: C07D417
IPC codes: A61K31, A61P1, C07D417, C07D285